Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients

• Sponsor: Children's Oncology Group (Other)
• Overall Status: Completed
• CT.gov ID: NCT01623856
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 483
• Location: 1

Study Details

Study Description

Brief Summary

This research studies genes associated with non-Hodgkin lymphoma in young patients. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

Condition or Disease	Intervention/Treatment	Phase
Childhood Burkitt Lymphoma; Childhood Lymphoblastic Lymphoma	Other: laboratory biomarker analysis

Detailed Description

OBJECTIVES:

1. To conduct a preliminary investigation of the effects of loci strongly and consistently associated in prior genome-wide association studies (GWAS) and validation studies of childhood/adolescent acute lymphoblastic leukemia (ALL), adult non-Hodgkin lymphoma (NHL), autoimmune diseases, and atopic diseases on the risk of NHL (lymphoblastic and Burkitt lymphomas) in children and adolescents.

OUTLINE:

DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.

Study Design

• Study Type: Observational
• Actual Enrollment: 483 participants
• Observational Model: Case-Control
• Time Perspective: Retrospective
• Official Title: Observational - Candidate Gene Variants and Childhood/Adolescent Non-Hodgkin Lymphoma: A Preliminary Investigation
• Study Start Date: Jun 1, 2012
• Actual Primary Completion Date: Jun 1, 2012
• Actual Study Completion Date: Jun 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Observational DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.	Other: laboratory biomarker analysis; Correlative studies

Outcome Measures

Primary Outcome Measures

1. Potential deviations from Hardy-Weinberg Equilibrium (HWE) [Baseline]

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A to 20 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Slides and/or other available specimens from patients diagnosed with lymphoblastic lymphoma (LL) or Burkitt lymphoma ( BL) enrolled on the Children Oncology Group (COG) protocols 5961, A5971, and ANHL01P1 collected at the time of diagnosis and currently housed at the Biopathology Center at Nationwide Children's Hospital

• Samples from non-Hispanic white patients

• DNA samples from 384 healthy, anonymous, non-Hispanic white blood donors used as controls

• See Disease Characteristics

• Not specified

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Children's Oncology Group	Monrovia	California	United States	91006-3776

Sponsors and Collaborators

• Children's Oncology Group
• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Amy Linabery, MD, Children's Oncology Group

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Children's Oncology Group
• ClinicalTrials.gov Identifier: NCT01623856
• Other Study ID Numbers: ANHL12B1; NCI-2012-01975
• First Posted: Jun 20, 2012
• Last Update Posted: May 7, 2015
• Last Verified: May 1, 2015

• Additional relevant MeSH terms: Burkitt Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma

Study Results

No Results Posted as of May 7, 2015